9
Participants
Start Date
February 22, 2022
Primary Completion Date
December 20, 2022
Study Completion Date
December 20, 2022
EN001
"EN001 intravenously (IV) in the treatment of Charcot-Marie-Tooth disease (CMT) type 1A Dosage for each group is as follows.~Dose group A (Low dose): 5.0x10\^5 cells/kg"
EN001
"EN001 intravenously (IV) in the treatment of Charcot-Marie-Tooth disease (CMT) type 1A Dosage for each group is as follows.~Dose group B (High dose): 2.5x10\^6 cells/kg"
Samsung Medical Center, Seoul
Lead Sponsor
ENCell
INDUSTRY